Clinical Trial Update: A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid. [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating benralizumab for Bullous Pemphigoid was terminated and results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bullous Pemphigoid

Drugs mentioned

• Benralizumab (benralizumab)

Snippet

Sponsor: AstraZeneca | Conditions: Bullous Pemphigoid | Phase 3 | Status: TERMINATED | Results posted: 2024-11-29